Clinical Trial Update: Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety and tolerability study of ISIS EIF4E Rx in combination with carboplatin and paclitaxel in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• ISIS EIF4E Rx
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED